Glenveigh Medical and Monica Healthcare Announce Distribution Agreement for Groundbreaking FDA Cleared Wireless Fetal Monitoring System

CHATTANOOGA, Tenn., Feb. 28, 2011 /PRNewswire/ -- Glenveigh Medical, LLC and Monica Healthcare Limited today announced an agreement for exclusive distribution rights in the United States as well as US territories and military bases for Monica Healthcare's AN24 wireless fetal monitoring system. The system recently received FDA regulatory clearance for use during labor and delivery. Marketed under the trade name Beacon by Monica™, the wireless fetal monitoring system will be available in U.S. hospitals exclusively through Glenveigh and promoted by Glenveigh's sales and distribution partner Norgenix Pharmaceuticals, LLC. Glenveigh is a life science and technology company focused on advancing the practice of obstetrics worldwide. United Kingdom-based Monica Healthcare develops wireless technologies for use in obstetrics.

"We are pleased to announce our partnership with Monica," stated C. David Adair, M.D., Founder, Chairman, and Chief Scientific Officer of Glenveigh Medical. "The Beacon by Monica™ is a break-though wireless device that monitors the fetal heart rate and uterine activity while allowing patients to ambulate without the usual nurse intervention."

Rick Proctor, President and CEO of Glenveigh Medical, added, "The Monica AN24 technology was validated in a rigorous clinical study that was reviewed by the FDA as part of the 510(k) clearance process."

The Beacon by Monica™ is simple to use, beltless, requires no wires to connect to a display or printer, and is designed to provide high levels of patient satisfaction. There is no need for the constant re-positioning of transducers which is required with current technology. Clinical trials also demonstrated that the device performs well in obese women where use of conventional technology can be challenging.

"This technology has already generated a tremendous amount of excitement and interest," stated Jeff Bradford, VP of Marketing for Glenveigh. "We are already receiving inquiries about product availability as clinicians are eager to try the device because it monitors the fetal ECG waveform."

Carl Barrett, Chief Executive Officer of Monica Healthcare is very optimistic about the potential for the Beacon by Monica™ in the United States. Barrett explained, "With the reputation of Glenveigh with clinicians, combined with Norgenix's nationwide sales force, we expect to penetrate the market rapidly."

For order inquires, call Norgenix at 877-320-5174 or visit www.norgenixpharma.com.

GLENVEIGH MEDICAL | www.glenveigh.com

MONICA HEALTHCARE LIMITED  |  www.monicahealthcare.com  

NORGENIX  |  www.norgenixpharma.com

SOURCE Glenveigh Medical, LLC